Fox fears neuro backlash as bapi makes pharma think again
This article was originally published in Scrip
The recent news that Pfizer, Janssen and Elan will kill development on bapineuzumab is particularly troubling for the Michael J. Fox Foundation, even thought the anti-beta-amyloid plaque monoclonal antibody was a prospective treatment for Alzheimer's, rather than Parkinson's, disease.
You may also be interested in...
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.